Cargando…

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0

Therapeutic response to neoadjuvant chemotherapy (NAC) for breast cancer based on Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 with FDG-PET/CT measurements was evaluated, and the results compared to those obtained with currently widely used Response Evaluation Criteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitajima, Kazuhiro, Miyoshi, Yasuo, Yamano, Toshiko, Odawara, Soichi, Higuchi, Tomoko, Yamakado, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nagoya University 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995733/ https://www.ncbi.nlm.nih.gov/pubmed/29915436 http://dx.doi.org/10.18999/nagjms.80.2.183

Ejemplares similares

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

(11)C-Choline positive but (18)F-FDG negative pancreatic metastasis from renal cell carcinoma on PET
por: Kitajima, Kazuhiro, et al.
Publicado: (2017)

Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in (18)F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
por: Higuchi, Tomoko, et al.
Publicado: (2019)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Tiny Obturator Node Metastasis from Prostate Cancer Not Shown by FDG-PET/CT, CT, or MRI Detected by (11)C-Choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis of stage I–III breast cancer: Multicenter study
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

(11)C-Choline-Avid but (18)F-FDG-Nonavid Prostate Cancer with Lymph Node Metastases on Positron Emission Tomography
por: Kitajima, Kazuhiro, et al.
Publicado: (2016)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
por: Vogsen, Marianne, et al.
Publicado: (2021)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

Diagnostic performance of (11)C-choline PET/CT and bone scintigraphy in the detection of bone metastases in patients with prostate cancer
por: Kitajima, Kazuhiro, et al.
Publicado: (2017)

Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update
por: Kitajima, Kazuhiro, et al.
Publicado: (2017)

Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2019)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)

Response criteria in solid tumors (PERCIST/RECIST) and SUV(max) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
por: Pierson, Cory, et al.
Publicado: (2018)

Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020)

Quantitation of cancer treatment response by 2-[(18)F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
por: O, Joo Hyun, et al.
Publicado: (2021)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Kitajima, Kazuhiro, et al.
Publicado: (2019)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

FDG-PET findings of Ameloblastoma: a case report
por: Seno, Satoshi, et al.
Publicado: (2015)

Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer
por: Li, Zongyao, et al.
Publicado: (2021)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Usefulness of Quantitative Bone Single Photon Emission Computed Tomography/Computed Tomography for Evaluating Response to Neoadjuvant Chemotherapy in a Patient with Periosteal Osteosarcoma
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dpi6lmub22nkj0ntgkf16s7qms